Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Thermo Fisher Scientific to Divest Microbiology Business to Astorg for $1.075 Billion – Strategic Portfolio Optimization

Fineline Cube Apr 28, 2026
Company Deals

Aureka Biotechnologies Secures $35M Series A+ Financing to Advance AuraIDE Platform for Functional Antibody Design

Fineline Cube Apr 28, 2026
Company Deals

Hangzhou’s Adcoris Licenses First-in-Class 5T4-Targeting ADC ACR246 to U.S. Biotech K2 Therapeutics in Deal Worth Up to $730 Million

Fineline Cube Apr 27, 2026
Company Deals

Sino Biopharmaceutical’s Chia Tai Tianqing and Shanghai Reunion Partner to Commercialize Respacio Hydrogel for Cervical Cancer Radiotherapy Protection in China

Fineline Cube Apr 27, 2026
Company Deals

Beijing QL Biopharma Files HKEX IPO Prospectus with Diversified GLP-1 Portfolio Targeting Global Obesity and Metabolic Disease Markets

Fineline Cube Apr 27, 2026
Policy / Regulatory

NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting

Fineline Cube Apr 27, 2026
Company Drug

Novartis Secures European Commission Approval for Rhapsido (remibrutinib) in Chronic Spontaneous Urticaria – Expanding Global BTK Inhibitor Franchise

Fineline Cube Apr 28, 2026
Company Drug

BeBetter Medicine Secures FDA Clearance for BEBT-701 Clinical Study – First-in-Class Dual-Target Therapy for Hypertension and High LDL-C

Fineline Cube Apr 28, 2026
Company Drug

Kexing Biopharm’s GB18 Receives FDA Approval for Tumor Cachexia Clinical Trial

Fineline Cube May 22, 2025

China-based Kexing Biopharm Co., Ltd. (SHA: 688136) announced receiving clinical trial approval from the US...

Company Drug

Accropeutics’ AC-201 Shows Positive Phase II Results in Psoriasis Treatment

Fineline Cube May 22, 2025

Suzhou-based Accropeutics Bioscience announced positive results from a Phase II study for its AC-201 in...

Company Drug

Simcere’s FGFR2b-Targeting ADC SIM0686 Enters Phase I Clinical Study

Fineline Cube May 22, 2025

China-based Simcere Pharmaceutical Group (HKG: 2096) announced the initiation of a Phase I clinical study...

Company Drug

Triastek’s T22 Gastric Retention Capsules Gain NMPA IND Clearance

Fineline Cube May 22, 2025

Nanjing-based Triastek Inc., a pioneer in 3D-printed pharmaceutical formulations, has obtained Investigational New Drug (IND)...

Company Drug

Boehringer Ingelheim’s Metalyse Approved in China for Acute Ischemic Stroke

Fineline Cube May 22, 2025

Germany-based pharmaceutical leader Boehringer Ingelheim announced receiving marketing approval from China’s National Medical Products Administration...

Company

Well Lead Medical to Set Up Subsidiary and Manufacturing Base in Indonesia

Fineline Cube May 22, 2025

Guangzhou-based medical catheter specialist Well Lead Medical Co., Ltd (SHA: 603309) plans to establish a...

Company Drug

Kelun-Biotech’s Sacituzumab Tirumotecan Accepted for NMPA Review for HR+, HER2- Breast Cancer

Fineline Cube May 22, 2025

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) announced that another indication approval filing for its...

Company Deals

Shandong Buchang Pharmaceuticals Partners with FBC for MF59 Adjuvant R&D

Fineline Cube May 22, 2025

China-based Shandong Buchang Pharmaceuticals Co., Ltd (SHA: 603858) announced plans to enter into an Entrusted...

Policy / Regulatory

HHS Implements Trump’s Order for Most-Favored-Nation Drug Pricing

Fineline Cube May 22, 2025

The U.S. Department of Health and Human Services (HHS) announced that it is taking immediate...

Company Drug

Nuance Pharma’s Ohtuvayre Meets Primary Endpoints in COPD Study

Fineline Cube May 22, 2025

China-based Nuance Pharma announced positive topline results from the ENHANCE-CHINA study (NCT05743075) for its nebulized...

Company Drug

AccurEdit Therapeutics’ ART001 Receives FDA RMAT Designation for ATTR

Fineline Cube May 22, 2025

China-based gene editing therapy specialist AccurEdit Therapeutics (Suzhou) Co., Ltd announced receiving Regenerative Medicine Advanced...

Company Deals

AstraZeneca Completes Acquisition of EsoBiotec for Up to USD 1 Billion

Fineline Cube May 22, 2025

UK-based major AstraZeneca (AZ; NASDAQ: AZN) announced the completion of its acquisition of EsoBiotec SA,...

Company Deals

Pulnovo Medical Raises Tens of Millions in New Financing Round

Fineline Cube May 21, 2025

Wuxi-based Pulnovo Medical Limited, a developer of medical devices for hypertension and heart failure, announced...

Company Deals Medical Device

PHASE Scientific Completes Series A Financing to Advance Urine-Based Diagnostics

Fineline Cube May 21, 2025

Hong Kong-based urine-based diagnostics specialist PHASE Scientific International Limited announced the completion of a Series...

Policy / Regulatory

China’s CDE Announces 94th Batch of Reference Preparations for Generic Evaluation

Fineline Cube May 21, 2025

China’s Center for Drug Evaluation (CDE) has selected the 94th batch of reference preparations for...

Company Deals

Merck KGaA Partners with IMEC to Develop Advanced Microphysiological Systems Platform

Fineline Cube May 21, 2025

German major Merck KGaA (ETR: MRK) this week announced a partnership with Belgium-based Interuniversity Microelectronics Centre...

Company Deals Drug

Antengene and MSD Collaborate on ATG-022 for Advanced Solid Tumors

Fineline Cube May 21, 2025

China-based Antengene Corporation Limited (HKG: 6996) has entered into a collaboration with US major Merck,...

Hospital Policy / Regulatory

China’s County Hospitals Show Improved Medical Service Capability in 2024

Fineline Cube May 21, 2025

The National Health Commission (NHC) released a notice reporting the status of the county hospital...

Company Drug

3SBio Registers Phase III Study for SSGJ-707 in Advanced NSCLC

Fineline Cube May 21, 2025

China-based 3SBio Inc. (HKG: 1530) announced this week the registration of the first Phase III...

Company Drug

Ascletis Pharma Initiates ASC47-103 Study in US for Obesity Treatment

Fineline Cube May 21, 2025

China-based Ascletis Pharma Inc. (HKG: 1672) announced the first subject dosing of the ASC47-103 study...

Posts pagination

1 … 150 151 152 … 658

Recent updates

  • Huahui Health Signs $1.9 Billion Global Licensing Deal with BeOne Medicines for Trispecific Antibody HH160 Targeting PD-1, CTLA-4, and VEGF-A
  • WuXi AppTec Reports Record Q1 2026 Results with 28.8% Revenue Growth and RMB 59.77B Backlog – Chemistry Segment Leads Expansion
  • Thermo Fisher Scientific to Divest Microbiology Business to Astorg for $1.075 Billion – Strategic Portfolio Optimization
  • Novartis Secures European Commission Approval for Rhapsido (remibrutinib) in Chronic Spontaneous Urticaria – Expanding Global BTK Inhibitor Franchise
  • Eli Lilly to Acquire Ajax Therapeutics for Up to $2.3 Billion to Expand JAK Inhibitor Portfolio in Myeloproliferative Neoplasms
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Others

Huahui Health Signs $1.9 Billion Global Licensing Deal with BeOne Medicines for Trispecific Antibody HH160 Targeting PD-1, CTLA-4, and VEGF-A

Company

WuXi AppTec Reports Record Q1 2026 Results with 28.8% Revenue Growth and RMB 59.77B Backlog – Chemistry Segment Leads Expansion

Company Deals

Thermo Fisher Scientific to Divest Microbiology Business to Astorg for $1.075 Billion – Strategic Portfolio Optimization

Company Drug

Novartis Secures European Commission Approval for Rhapsido (remibrutinib) in Chronic Spontaneous Urticaria – Expanding Global BTK Inhibitor Franchise

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.